Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
Background: Chronic Hepatitis-C virus [HCV] infection is endemic in Egypt, with the highest prevalence worldwide. There are few studies on the effectiveness and safety of direct acting antivirals in treating geriatric patients with chronic HCV. Aim of the work: This study aimed to determine the eff...
Guardado en:
Autores principales: | Mohamed G. Mohamed, Mohamed B. Bastawy, Mostafa A. Elhawary, Mohamed R. Rashed |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Al-Azhar University, Faculty of Medicine (Damietta)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6200c19577674c1fbc192a343a18ef86 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol S, et al.
Publicado: (2016) -
The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
por: Irina RUSU, et al.
Publicado: (2020) -
Possible acute rejection associated with the use of the new antihepatitis C virus medications
por: Khaled Ar Karkout, et al.
Publicado: (2019) -
Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
por: Kutala BK, et al.
Publicado: (2017) -
SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
por: Arif Qayyum Khan, et al.
Publicado: (2021)